Jefferies Initiates Coverage of Caris Life Sciences Inc. (CAI) With a Buy Rating

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the most oversold healthcare stocks to invest in. Jefferies initiated coverage of Caris Life Sciences Inc. (NASDAQ:CAI) with a Buy rating on April 13, setting a $28 price target on the stock. The firm told investors that it sees “secular tailwinds” in the oncology diagnostics space from improving therapies and declining sequencing costs. However, it also cited the “ongoing polarization between the leaders and laggards”, adding that the firm views Caris Life Sciences Inc. (NASDAQ:CAI) and Veracyte as “compelling stocks” given their profitability, valuations, and pipelines.

In another development, Goldman Sachs initiated coverage of Caris Life Sciences Inc. (NASDAQ:CAI) with a Buy rating and $27 price target on April 1. The firm told investors in a research note that the company can continue to see volume growth within the therapy selection offering, adding that it also believes Caris Life Sciences Inc. (NASDAQ:CAI) holds the potential to unlock additional addressable market opportunities through upcoming launches in its pipeline.

Caris Life Sciences Inc. (NASDAQ:CAI) provides diagnostics and anatomic pathology services. The company’s services are offered throughout the United States, Europe, Australia and other international markets.

While we acknowledge the risk and potential of CAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.